866-997-4948(US-Canada Toll Free)

Global Markets for Neglected Tropical Disease Treatments

Published By :

BCC Research

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 161 Pages


The global market for neglected tropical diseases should reach $2.6 billion by 2021 from $1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.
The market for malaria treatments is expected to grow from $513.5 million in 2016 to $757.9 million in 2021 at a CAGR of 8.1% for the period 2016-2021.
The dengue (vaccine) segment of the neglected tropical diseases market is expected to grow from $299.4 million in 2016 to $1.3 billion in 2021 at a CAGR of 34.8% for the period 2016-2021.

##img_0##

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 4 Market Overview
Chapter 5 Market Influencing Factors
Chapter 6 Research and Development
Chapter 7 Patent Review
Chapter 8 Company Profiles
Total Addressable Market
Malaria
Malaria - Market Share by Geography
Leishmaniasis
Leishmaniasis - Market Share by Geography
Schistosomiasis
Schistosomiasis - Market Share by Geography
Lymphatic Filariasis
Lymphatic Filariasis - Market Share by Geography
Chagas Disease
Chagas Disease - Market Share by Geography
African Trypanosomiasis
Dengue
Dengue - Market Share by Geography
Ebola
Zika
Zika - Market Share by Geography
Donations by Pharmaceutical Companies: Access to Medicines
Market Drivers
Market Deterrents
Malaria
Leishmaniasis
Lymphatic Filariasis
Chagas Disease
African Trypanosomiasis
Dengue
Ebola
Zika
Malaria
Leishmaniasis
Schistosomiasis
Lymphatic Filariasis
Chagas Disease
African Trypanosomiasis
Dengue
Ebola
Zika
Unmet Needs
Malaria
Leishmaniasis
Schistosomiasis
Lymphatic Filariasis
Chagas Disease
African Trypanosomiasis
Dengue
Ebola
Zika
Malaria
Clinical Trials in Malaria
Leishmaniasis
Clinical Trials in Leishmaniasis
Schistosomiasis
Clinical Trials in Schistosomiasis
Lymphatic Filariasis
Clinical Trials in Lymphatic Filariasis
Chagas Disease
African Trypanosomiasis
Dengue
Ebola
Zika
Clinical Trials in Chagas Disease
Clinical Trials in African Trypanosomiasis
Clinical Trials in Dengue
Clinical Trials in Ebola
Clinical Trials in Zika
Malaria
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Leishmaniasis
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Schistosomiasis
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Lymphatic Filariasis
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Chagas Disease
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
African Trypanosomiasis
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Dengue
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Ebola
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
Zika
Patent Review by Assignee
Patent Review by Year
Patent Review by Country
Patent Review by Type
ANACOR PHARMACEUTICALS (NOW PFIZER)
BAYER
BUTANTAN
(DNDI) DRUGS FOR NEGLECTED DISEASES INITIATIVE
EISAI
GILEAD SCIENCES
GLAXOSMITHKLINE
MERCK
(MMV) MEDICINES FOR MALARIA VENTURE
NOVARTIS
THE PATH MALARIA VACCINE INITIATIVE
SABIN VACCINE INSTITUTE
SANOFI-AVENTIS/SANOFI PASTEUR
TAKEDA
Chapter 9 Appendix: Abbreviations
Research Portfolio and Alliances
Access to Medicines
Research Portfolio and Alliances
Research Portfolio and Alliances
Research Portfolio
Research Portfolio and Alliances
Access to Medicines
Research Portfolio and Alliances
Access to Medicines
Research Portfolio and Alliances
Research Portfolio and Alliances
Access to Medicines
Access to Medicines
Research Portfolio and Alliances
Research Portfolio and Alliances
Access to Medicines
Research Portfolio and Alliances
Research Portfolio and Alliances
Research Portfolio and Alliances
Access to Medicines:
Research Portfolio and Alliances
Research Portfolio and Alliances
Chapter 3 Disease Overview
Malaria
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Leishmaniasis
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Schistosomiasis
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Lymphatic Filariasis
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Chagas Disease
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
African Trypanosomiasis
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Dengue
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Ebola
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment
Zika
Incidence and Geographical Distribution
Etiology and Symptoms
Socioeconomic Burden
Current Method of Treatment

List of Table

Summary Table : Global Market for Neglected Tropical Diseases, by Indication, Through 2021
Table 1 : Key Trends in Neglected Tropical Diseases
Table 2 : Estimated Malaria Incidence (per 1,000 at Risk), 2000-2015
Table 3 : Suspected Malaria Cases, 2010-2015
Table 4 : Confirmed Malaria Cases, 2010-2015
Table 5 : Estimated Spending on Malaria Treatment in Sub-Saharan Africa, 2010-2014
Table 6 : WHO Guidelines for Treatment of Malaria
Table 7 : Number of Cases of CL in Select High Burden Countries, 2010-2014
Table 8 : Number of Cases of VL in Select High Burden Countries, 2010-2014
Table 9 : Incidence of CL and VL in High Burden Countries, 2014
Table 10 : Global Disease Burden of Leishmaniasis, 2015
Table 11 : WHO Guidelines for Treatment of Leishmaniasis
Table 12 : Number of People Treated Globally, 2010-2014
Table 13 : Global Disease Burden of Schistosomiasis, 2015
Table 14 : Global Disease Burden of Lymphatic Filariasis, 2015
Table 15 : Prevalence and Incidence (Number) of Chagas Disease, 2015
Table 16 : Global Disease Burden of Chagas Disease, 2015
Table 17 : Prevalence and Incidence (Number) of Chagas Disease, 2015
Table 18 : Global Disease Burden of African Trypanosomiasis, 2015
Table 19 : Prevalence and Incidence (Number) of Dengue Cases, 2015
Table 20 : Reported Cases and Deaths in Ebola Outbreaks, 2007-2016
Table 21 : Zika Burden, 2015-2016
Table 22 : Global Addressable Market for Neglected Tropical Diseases, by Indication, Through 2021
Table 23 : Global Addressable Market for Malaria, by Region, Through 2021
Table 24 : Global Addressable Market for Leishmaniasis, by Region, Through 2021
Table 25 : Global Addressable Market for Schistosomiasis, by Region, Through 2021
Table 26 : Global Addressable Market for Lymphatic Filariasis, by Region, Through 2021
Table 27 : Global Addressable Market for Chagas Disease, by Geography, Through 2021
Table 28 : Global Addressable Market for Dengue, by Region, Through 2021
Table 29 : Global Addressable Market for Zika, by Region, Through 2021
Table 30 : Drug Donation Commitments, by WHO
Table 31 : Malaria Development Pipeline and Recent Launches
Table 32 : Leishmaniasis Development Pipeline and Recent Launches
Table 33 : Schistosomiasis Development Pipeline and Recent Launches
Table 34 : Lymphatic Filariasis Development Pipeline and Recent Launches
Table 35 : Chagas Disease Development Pipeline and Recent Launches
Table 36 : African Trypanosomiasis Development Pipeline and Recent Launches
Table 37 : Dengue Development Pipeline and Recent Launches
Table 38 : Ebola Development Pipeline and Recent Launches
Table 39 : Zika Development Pipeline and Recent Launches
Table 40 : Number of Patent Applications, Malaria, by Assignee
Table 41 : Number of Patent Applications, Malaria, by Year, 2010-2015
Table 42 : Number of Patent Applications, Malaria, by Country
Table 43 : Number of Patent Applications, Malaria, by Type
Table 44 : Number of Patent Applications, Leishmaniasis, by Assignee
Table 45 : Number of Patent Applications, Leishmaniasis, by Year, 2010-2015
Table 46 : Number of Patent Applications, Leishmaniasis, by Country
Table 47 : Number of Patent Applications, Leishmaniasis, by Type
Table 48 : Number of Patent Applications, Schistosomiasis, by Assignee
Table 49 : Number of Patent Applications, Schistosomiasis, by Year, 2010-2015
Table 50 : Number of Patent Applications, Schistosomiasis, by Country
Table 51 : Number of Patent Applications, Schistosomiasis, by Type
Table 52 : Number of Patent Applications, Lymphatic Filariasis, by Assignee
Table 53 : Number of Patent Applications, Lymphatic Filariasis, by Year, 2010-2015
Table 54 : Number of Patent Applications, Lymphatic Filariasis, by Country
Table 55 : Number of Patent Applications, Lymphatic Filariasis, by Type
Table 56 : Number of Patent Applications, Chagas Disease, by Assignee
Table 57 : Number of Patent Applications, Chagas Disease, by Year, 2010-2015
Table 58 : Number of Patent Applications, Chagas Disease, by Country
Table 59 : Number of Patent Applications, Chagas Disease, by Type
Table 60 : Number of Patent Applications, African Trypanosomiasis, by Assignee
Table 61 : Number of Patent Applications, African Trypanosomiasis, by Year, 2010-2015
Table 62 : Number of Patent Applications, African Trypanosomiasis, by Country
Table 63 : Number of Patent Applications, African Trypanosomiasis, by Type
Table 64 : Number of Patent Applications, Dengue, by Assignee
Table 65 : Number of Patent Applications, Dengue, by Year, 2010-2015
Table 66 : Number of Patent Applications, Dengue, by Country
Table 67 : Number of Patent Applications, Dengue, by Type
Table 68 : Number of Patent Applications, Ebola, by Assignee
Table 69 : Number of Patent Applications, Ebola, by Year, 2010-2016
Table 70 : Number of Patent Applications, Ebola, by Country
Table 71 : Number of Patent Applications, Ebola, by Type
Table 72 : Number of Patent Applications, Zika, by Assignee
Table 73 : Number of Patent Applications, Zika, by Year, 2010-2016
Table 74 : Number of Patent Applications, Zika, by Country
Table 75 : Number of Patent Applications, Zika, by Type
Table 76 : Abbreviations Used in Neglected Tropical Diseases Landscape
Table 77 : Glossary of Terms Used in Neglected Tropical Diseases Landscape
Table 78 : Report Sources

List of Chart

Summary Figure : Global Market for Neglected Tropical Diseases, by Indication, 2015-2021
Figure 1 : Global Number of Malaria Caused Deaths, 2011-2015
Figure 2 : Global Number of Leishmaniasis Caused Deaths, 2011-2015
Figure 3 : Global Leishmaniasis Years of Life Lost*, 2011-2015
Figure 4 : Global Number of Schistosomiasis Caused Deaths, 2011-2015
Figure 5 : Global Schistosomiasis Years of Life Lost*, 2011-2015
Figure 6 : Number of Lymphatic Filariasis Endemic Countries, by Region
Figure 7 : Number of Chagas Disease Caused Deaths, 2011-2015
Figure 8 : Global Chagas Disease Years of Life Lost*, 2011-2015
Figure 9 : Number of Cases of African Trypanosomiasis, T.b. gambiense, 2011-2015
Figure 10 : Number of Cases of African Trypanosomiasis, T.b. rhodesiense, 2011-2015
Figure 11 : Global Number of African Trypanosomiasis Caused Deaths, 2011-2015
Figure 12 : Global African Trypanosomiasis Years of Life Lost*, 2011-2015
Figure 13 : Average Annual Number of Dengue Fever Cases, 1960-2007
Figure 14 : Number of Cases in American Region, 2012-2016
Figure 15 : Incidence Rate (per 100,000 Inhabitants) in American Region, 2012-2016
Figure 16 : Global Number of Dengue Caused Deaths, 2011-2015
Figure 17 : Global Dengue Caused Years of Life Lost*, 2011-2015
Figure 18 : Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Cases, March 2014-February 2016
Figure 19 : Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Deaths, March 2014-February 2016
Figure 20 : Number of Countries (Y) with Number of Confirmed Zika Cases (X), by American Region, 2015-2016
Figure 21 : Global Addressable Market for Neglected Tropical Diseases, by Indication, 2015-2021
Figure 22 : Global Market for Malaria, by Region, 2014-2021
Figure 23 : Global Market for Leishmaniasis, by Region, 2014-2021
Figure 24 : Global Market for Schistosomiasis, by Region, 2014-2021
Figure 25 : Global Market for Lymphatic Filariasis, by Region, 2014-2021
Figure 26 : Global Market for Chagas Disease, by Geography, 2014-2021
Figure 27 : Global Market for Dengue, by Region, 2014-2021
Figure 28 : Global Market for Zika, by Region, 2014-2021
Figure 29 : Clinical Trials in Malaria, by Intervention Type, January 2005-September 2016
Figure 30 : Top 20 Sponsors/Collaborators, by Clinical Trials in Malaria, January 2005-September 2016
Figure 31 : Clinical Trials in Leishmaniasis, by Intervention Type, January 2005-September 2016
Figure 32 : Key Sponsors/Collaborators, Clinical Trials in Leishmaniasis, January 2005-September 2016
Figure 33 : Clinical Trials in Schistosomiasis, by Intervention Type, January 2005-September 2016
Figure 34 : Key Sponsors/Collaborators, Clinical Trials in Lymphatic Filariasis, January 2005-September 2016
Figure 35 : Clinical Trials in Chagas Disease, by Intervention Type, January 2005-September 2016
Figure 36 : Key Sponsors/Collaborators, Clinical Trials in Chagas Disease, January 2005-September 2016
Figure 37 : Clinical Trials in Dengue, by Intervention Type, January 2005-September 2016
Figure 38 : Key Sponsors/Collaborators, Clinical Trials in Dengue, January 2005-September 2016
Figure 39 : Clinical Trials in Ebola, by Intervention Type, January 2005-September 2016
Figure 40 : Key Sponsors/Collaborators, Clinical Trials in Ebola, January 2005-September 2016
Figure 41 : Key Sponsors/Collaborators, Clinical Trials in Zika, January 2005-September 2016
Figure 42 : Patent Share for Treatment and Preventive Medicine in Malaria, by Year
Figure 43 : Patent Share for Treatment and Preventive Medicine in Malaria, US and non-US
Figure 44 : Patent Share for Treatment and Preventive Medicine in Leishmaniasis, by Year
Figure 45 : Patent Share for Leishmaniasis, US and non-US
Figure 46 : Patent Share for Treatment and Preventive Medicine in Schistosomiasis, by Year
Figure 47 : Patent Share for Schistosomiasis, U.S. and non-U.S.
Figure 48 : Patent Share for Treatment and Preventive Medicine in Lymphatic Filariasis, by Year
Figure 49 : Patent Share for Lymphatic Filariasis, U.S. and non-U.S.
Figure 50 : Patent Share for Treatment and Preventive Medicine in Chagas Disease, by Year
Figure 51 : Patent Share for Chagas Disease, by U.S. and non-U.S.
Figure 52 : Patent Share for Treatment and Preventive Medicine in African Trypanosomiasis, by Year
Figure 53 : Patent Share for African Trypanosomiasis, US and non-US
Figure 54 : Patent Share for Treatment and Preventive Medicine in Dengue, by Year
Figure 55 : Patent Share for Dengue, U.S. and non-U.S.
Figure 56 : Patent Share for Treatment and Preventive Medicine in Ebola, by Year
Figure 57 : Patent Share for Ebola, U.S. and non-U.S.
Figure 58 : Patent Share for Treatment and Preventive Medicine in Zika, by Year
Figure 59 : Patent Share for Zika, U.S. and Non-U.S.
Figure 60 : DNDi - Research Portfolio, by Phase of Development
Figure 61 : DNDi - Research Portfolio, by Indication
Figure 62 : GlaxoSmithKline - Research Portfolio, by Phase of Development
Figure 63 : GlaxoSmithKline - Research Portfolio, by Indication
Figure 64 : MMV - Research Portfolio, by Phase of Development
Figure 65 : MMV - Research Portfolio, by Partner

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *